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clinical characteristics and outcome for patients undergoing small versus large culprit
vessel PPCI in our unit.
Methods: We included all patients who underwent PPCI in our unit between Sept 2009
and May 2011. They were divided into two groups according to the size of the largest
balloon or stent used in the culprit lesion.
Results: Of the 1132 patients who underwent PPCI in our unit during the study period,
we excluded 30 (2.7%) patients who did not have either a balloon or stent used in the
culprit lesion. Of the remaining 1102 patients, 569 (51.6%) had small (3 mm) vessel
PPCI and 533 (48.4%) had large (3 mm) vessel PPCI. Patients with small vessel PPCI
were significantly older, more likely to be female and have anterior STEMI with less use
of thrombectomy device, but with significantly higher drug eluting stent (DES) usage.
There was significantly higher in-hospital mortality (5.3% vs 2.8%, OR 1.9, 95% CI 1-3.6,
p 0.047), 30-day mortality (8.4% vs 3.6%,OR 2.5, 95% CI 1.4-4.3, p 0.0009) and 30-day
stent thrombosis (1.2% vs 0, p 0.02) in the small vessel PPCI group compared to large
vessel PPCI group. On binary logistic regression analysis of small vessel PPCI patients
(covariates used: female sex, Age 75 yrs, cardiogenic shock, diabetes, LAD PCI and
DES use), the positive predictors of 30-day mortality were age75 yrs (OR 6.1, 95% CI
2.9 to 12.5, p0.0001) and cardiogenic shock (OR 9.9, 95% CI 4.3-22.6, p0.0001) with
DES use (OR 0.4, 95% CI 0.2-0.8, p 0.01) being the only negative predictor of mortality.
N (%)
Small (<3 mm)
vessel
Large (> 3 mm)
vessel
p valueN 569 N 533
Age (meanSD,
range)
66.813.5, 25-96 62.913.1, 26-99 0.0001
Age  75 yrs 172 (30.2) 94 (17.6) 0.0001
Female 203 (35.7) 94 (17.6) 0.0001
Diabetes 68 (11.8) 63 (11.8) 1.0
Cardiogenic shock 42 (7.4) 42 (7.9) 0.73
Previous MI 65 (11.4) 69 (12.9) 0.46
Previous PCI 33 (5.8) 42 (7.9) 0.19
Previous CABG 11 (1.9) 16 (3) 0.33
LAD PCI 293 (51.5) 218 (40.9) 0.0005
Thrombectomy use 363 (63.8) 424 (79.5) 0.0001
Drug eluting stent use
(at least one)
363 (63.8) 289 (54.2) 0.001
Conclusions: In this large consecutive PPCI series from a single center, small culprit
vessel size was associated with significantly higher 30-day mortality, more than double
the mortality seen in patients with a large culprit vessel.
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Background: Elderly constitute an increasing proportion of all patients, who are
admitted for ACS to the hospital, but on the other hand increased age has been identified
as an important risk factor for death or recurrent MI in this subset. Furthermore elderly
patients are at higher risk for complications with interventional procedures, therefore the
overall benefit in such procedures, facing a limited life expectancy in elderly patients
anyway, still remains uncertain. The purpose of this study was to identify predictors of
longtime survival in either interventionally or conservatively treated elderly patients with
ACS in a large consecutive series of elderly ( 75 years).
Methods: Between 01/05 and 11/07 1001 patients  75 ys. were admitted with the
diagnosis of ACS in our hospital. Records were evaluated and patients were identified on
the basis of their discharge diagnosis. Adverse outcome, defined as the appearance of
death, myocardial infarction, complicated hospital stay, pneumonia and interventional
complications like bleeding, stroke and reinfarction etc. was evaluated. Using a multi-
variate regression analysis, factors which predicted long-time mortality were identified.
Results: Out of 1001 patients (mean age 815 Jahre, 512 (51.1% female), Killip-class
1,40,75, EF 4715%) 776 [77.5 %] were treated invasively; wherease 247 [22.5%]
were teated conservatively. Mean survival for conservatively treated NSTEMI patients
was 78953 vs. 123729 in the invasively treated patients, in the STEMI group survival
was 706128 for conservatively and 123844 days for interventionally treated patients
respectively (p0.001). As predictors of long term mortality we identified renal failure
((p0.001), insulin-treated Diabetes (p0.001); chronic obstructive pulmonary disease
(p0.002), Grace-Score (p0.002) intervention (p0.003), increased body mass index
(p0.018) and age (p0.042).
Conclusions: In our large data base of 1001 patients age was not the main predictor of
long-time mortality. Therefore advanced age should not be the main factor in decision
making for conservative or invasive treatment in elderly patients with ACS and an
invasive strategy should be offered also to elderly patients.
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Background: An emphasis on sensitivity in the diagnosis of ST-segment elevation
myocardial infarction necessitates a certain degree of ‘false positive’ diagnoses. Little is
known about the long-term outcomes of those ultimately found to lack a culprit coronary
artery occlusion despite a putative STEMI diagnosis.
Methods: We analyzed a registry of all STEMI diagnoses established in the Emergency
Department (ED) at two urban centers from 2008 to 2011. Subsequent death, ED visits,
hospitalizations, and cardiac procedures at our study centers following index hospitaliza-
tion were evaluated. Statistical analyses were performed using Student’s t tests and
regression analyses.
Results: During a median follow up of 20 months (IQR12.2-29.6 months), 13 of 153
‘false positive’ STEMI diagnoses died as compared to 32 of 248 ‘true positives’ (p 
0.091) (Figure 1). After adjusting for traditional risk factors, all-cause mortality was not
statistically different between ‘true’ and ‘false’ STEMI diagnoses (AOR 2.26, 95% CI
0.21-24.23, p0.499). However, false positive status was associated with a significantly
higher likelihood of a recurrent visit to the emergency department (AOR 2.73, 95% CI
1.24-6.02 p0.01), and an increased rate of re-hospitalization (1.04 additional hospital-
izations, 95% CI 0.21-1.86, p0.01) though they also had a trend towards fewer
subsequent myocardial infarctions (AOR 0.92, 95% CI 0.17 to 0.01, p0.07).
Conclusions: Patients with ‘false positive’ STEMI diagnoses have rates of long term
all-cause mortality comparable to a ‘true’ STEMIs population and have potentially greater
rates of recurrent resource utilization. Patients diagnosed with a putative STEMI but found
to lack a culprit coronary artery occlusion on angiography remain at great risk for
subsequent events and require further study.
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Background: The aim of this study was to investigate the effects of baseline anaemia on
the outcome of patients treated by primary percutaneous intervention (PPCI) for ST
elevation myocardial infarction.
Methods: We undertook a retrospective cohort study of 2418 STEMI patients treated
with PPCI between January 2004 and August 2010 at a single centre. We investigated the
outcome of patients with anaemia compared to patients with a normal haemoglobin level.
Anaemia was defined according to the WHO definition of haemoglobin (Hb) less than 12
g/dl for females and 13 g/dl for males. We also calculated hazard ratios (HRs) using a
stratified model according to haemoglobin level.
Results: 471 (19%) patients were anaemic at presentation. The anaemic cohort were
older (72.2 vs. 62.4, p0.0001), had higher incidence of diabetes (28% vs. 16%,
p0.0001), hypertension (57% vs. 43%, p0.01), hypercholesterolaemia (48% vs. 40%,
p0.007), previous PCI (15% vs. 9%, p0.0001), previous MI (23% vs. 12%, p0.002)
and cardiogenic shock (12% vs. 5%, P0.0001). Over a mean follow-up period of 3-years
there was significantly higher all cause mortality in the anaemic group compared to the
normal Hb group (20.4% vs. 13.5%, p0.0001). However, after adjustment for all
variables using multivariate analysis, anaemia (based on the WHO definitions) was not an
independent predictor of mortality or major adverse cardiac events (MACE) over the
follow-up period. However, when we used a stratified model by g/dL we found that in
men there was an increased risk of adverse outcome with low Hb. There appeared to be
a threshold value of haemoglobin (13 g/dL) associated with increased risk. Although a
similar trend was observed for women no significant difference was observed.
Conclusions: Patients with anaemia undergoing primary PCI are at higher risk of an
adverse outcome. Anaemia is a simple and powerful marker of poor prognosis. Although
after multivariate analysis, anaemia (based on WHO definitions) does not appear to be an
independent predictor of all-cause mortality or MACE after primary PCI, in men there
appears to be a threshold value of Hb, below which there is an associated increased risk.
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Background: The aim of our study was to determine the short and long-term outcomes
between patients undergoing PPCI during ‘normal hours’ (i.e. In-hours) versus ‘out-of-
hours’. Our primary end point was mortality with a follow-up upto five years.
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Methods: This was an observational study of 3041 STEMI patients treated with PPCI
between 2004 and 2011 at a single centre with follow-up for a median of 3.0 years (IQR
range: 1.2-4.6 years). The primary end-point was long-term all cause mortality and major
adverse cardiac events (MACE).
Results: There were 1044 (%) patients who underwent PPCI during ‘In-hours’’ (IHs)
compared to 1649 (%) patients ‘out-of-hours’ (OFHs). Baseline characteristics were
similar between the two groups. Over the follow-up there were significant differences in
rates of mortality (IHs 7.4% vs. OFHs 7.2%, p0.442) or MACE (IHs 15.4% vs. OFHs
14.1%, p0.192 - Figure 1) between the two groups. In addition, there were no significant
differences in door-to-balloon times between the two groups (IHs 67.8mins vs 69.6mins,
p0.709). After adjustment for confounding variables using multivariate analysis, OFHs
PPCI was not an independent predictor of mortality (HR 1.04 95% CI: 0.78-1.39). In
addition, door-to-balloon time was not an independent predictor of mortality (HR 1.43
95% CI: 0.94-2.16).
Conclusions: Patients undergoing PPCI during ‘out-of-hours’ have similar outcomes to
patients undergoing PPCI during ‘In-hours’. In addition, we did not find any significant
delay in door-to-balloon times in the ‘out-of-hours’ group. This data adds to the growing
literature suggesting ‘out-of-hours’ PPCI is safe.
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Background: The activation criteria for primary percutaneous coronary intervention
(PPCI) includes chest pain in association with either ST-segment elevation (STE) or
new-onset left bundle branch block (LBBB) on the ECG. However, defining LBBB as
new is challenging acutely and the poor specificity of indeterminate chronicity LBBB may
result in unnecessary PPCI activations. Published data are conflicting with regard to the
utility of LBBB as a triage criterion for PPCI and the subsequent outcomes are undefined.
Methods: Consecutive patients attending a single UK tertiary centre for presumed PPCI
between September 2008 and December 2011 were included (n2192). The activation ECG
was obtained from the hospital PPCI database, as were demographic data. Outcome data were
obtained from notes and national databases. MACE was defined as a composite of mortality
and unplanned revascularisation. Two interventionists blinded to patient outcome reviewed the
angiographic images and adjudicated if the activation was appropriate.
Results: Chest pain with LBBB (LBBB-activation) occurred in 120 patients (5.5%) of
the overall PPCI cohort. Comparing LBBB-activations to those with STE demonstrated
that LBBB-activations were older (mean age 70.712.2 vs 64.613.4 yrs; p0.001) and
less likely to be male (66.7% vs 76.8%; p0.004). Other baseline demographics were
similar. 21 (17.5%) patients presenting with LBBB-activation had an acute thrombotic
coronary occlusion confirmed at angiography and received PPCI. The final adjudicated
diagnoses for LBBB-activations were acute coronary syndrome (ACS) (39.2%), non-ACS
cardiac (33.3%) and non-cardiac (27.5%). One-year mortality and MACE were higher for
appropriate LBBB-activations than the STEMI activations (31.3% vs 7.2%, p0.002 and
40.0% vs 11.9%, p0.007 respectively).
Conclusions: Less than half of LBBB-activations had an ACS and, of these, only half
had a thrombotic coronary occlusion requiring PPCI. However, LBBB-activations have a
significantly worse prognosis and merit urgent referral. Enhanced triage methods are
required to correctly identify acute MI requiring PPCI in those with LBBB.
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Background: There is a paucity of evidence on the optimal medical therapy in patients
with hypertension and acute myocardial infarction (MI) particularly on the role of calcium
channel blockers (CCB).
Methods: A total of 5,076 hemodynamically stable patients who underwent primary PCI
for ST-elevation MI within 12 hours after symptom onset were dichotomized according
to the presence of antecedent hypertension. Benefit of angiotensin-converting enzyme
inhibitors (ACEI) or angiotensin-receptor blockers (ARB), beta blockers, CCB, and
diuretics administered during hospitalization was compared between the 2 groups during
12-month follow-up.
Results: Patients with hypertension (n  2,229, 43.9%) had higher in-hospital mortality
(2.2% vs. 1.1%, p  0.02), but adjusted 12-month rates of death and death/MI were not
statistically different between the groups. ACEI/ARB reduced 12-month mortality both in
patients with hypertension (hazard ratio [HR] 0.34, 95% confidence interval [CI]
0.22-0.53, p  0.001) and in patients without hypertension (HR 0.39, 95% CI 0.24-0.64,
p  0.001). Beta blocker therapy significantly reduced 12-month mortality in patients
with hypertension (HR 0.55, 95% CI 0.34-0.90, p  0.02). In contrast, use of CCB and
diuretics was associated with increased 12-month mortality in patients with hypertension
(HR 2.09, 95% CI 1.19-3.66, p  0.01 and HR 2.03, 95% CI 1.31-3.16, p  0.002,
respectively).
Conclusions: In patients with hypertension undergoing primary PCI for ST-elevation
MI, in-hospital mortality was higher and use of CCB and diuretics was associated with
increased 12-month mortality, compared to patients without hypertension.
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Background: Distal embolization (DE) is a major contributor to no-reflow and greater
myocardial necrosis in STEMI. Manual Aspiration Thrombectomy (MAT) may reduce
intra-procedural thrombotic complications, DE and improve procedural and clinical
outcomes. Whether these findings are applicable to contemporary interventional practice
is unknown.
Methods: The INFUSE-AMI trial randomized 452 pts with anterior STEMI due to prox
or mid LAD occlusion, treated with bivalirudin, to intracoronary bolus abciximab
delivered locally via the ClearWay RX catheter vs. no abciximab, and to MAT with the
Export catheter vs. no MAT. The primary endpoint was core laboratory assessed MRI
infarct size (IS, % of LV mass) at 30 days. Presence of thrombus and DE were assessed
at an independent angiographic core laboratory.
Results: Median age was 61y, 74% were men and 11% had diabetes. Intracoronary
abciximab reduced median IS: 15.1 [6.8-22.7] vs. 17.9 [10.3-25.4], P0.03, whereas
MAT did not. Thrombus was present at baseline in 85.8% and 87.0% of the MAT and no
MAT groups, respectively (P0.7), and thrombus area was 19.45  11.04 and 20.27 
11.89 mm2 (P0.55). Balloon pre-dilatation was performed in 47.5% of MAT and 66.7%
of no MAT (P0.0001). Immediately pre-stenting, thrombus was present in 48.8% and
66.9% of MAT and no MAT (P0.0004). Similarly, thrombus area was reduced with
MAT vs. no MAT (11.68 8.17 vs 15.43 9.73 mm2), P0.008. DE was seen in 1.7%
(4/232) and 3.6% (8/223) of MAT and no MAT (P0.22). There were no significant
differences between MAT and no MAT with regard to TIMI flow grades or myocardial
blush grades at baseline or post stenting. These parameters, however, were worse in no
MAT immediately before stenting: TIMI 0/1 13.6% vs. 38.7%; MBG 0/1 22.6% vs.
48.0%, for MAT and no MAT (P0.0001 for both).
Conclusions: In the INFUSE-AMI trial, the incidence of DE in pts undergoing stenting
for STEMI was low and not influenced by use of MAT. MAT resulted in smaller
thrombus burden and better intra-procedural myocardial perfusion pre-stenting compared
to no MAT, but this advantage was lost after stenting. These findings offer mechanistic
insights into why MAT failed to reduce infarct size in the INFUSE-AMI trial.
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